Viewing Study NCT00486720


Ignite Creation Date: 2025-12-25 @ 4:12 AM
Ignite Modification Date: 2026-03-02 @ 10:36 PM
Study NCT ID: NCT00486720
Status: TERMINATED
Last Update Posted: 2015-07-03
First Post: 2007-06-14
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Myelodysplastic Syndromes View
None Blood Disease View
None Bone Marrow Disease View
Keywords: